Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges

X Mielgo-Rubio has an advisory role with Boehringer Ingelheim, AstraZeneca and Bristol Myers Squibb; is a member of the speakers bureau for Roche, AstraZeneca, Bristol Myers Squibb, MSD and Abbott; and receives other research funding from Bristol Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

留言 (0)

沒有登入
gif